Core Viewpoint - Medifast has entered a Cooperation Agreement with Steamboat Capital, leading to the nomination of Parsa Kiai and Jeff Rose as independent director candidates for the 2026 Annual Meeting of Stockholders, scheduled for May 19, 2026 [1][2][3] Company Leadership Changes - Medifast's Board of Directors has decided that directors Jeffrey Brown and Michael Hoer will not seek reelection, while Dan Chard will remain as Chairman and CEO until June 1, 2026, after which Nicholas Johnson is expected to succeed him as CEO [2][3] Strategic Focus and Financial Performance - The company aims to return to profitability, grow its business and independent coach network, and maintain a commitment to scientific innovation, with a focus on improving financial performance to maximize stockholder returns [3] - Medifast reported a fourth quarter 2025 revenue of $75.1 million, with a net loss of $18.1 million, or $1.65 per diluted share [14] Cooperation Agreement Details - The Cooperation Agreement includes customary standstill and voting provisions through the company's 2027 Annual Meeting of Stockholders, and it will be filed with the Securities and Exchange Commission [3] Background of New Directors - Parsa Kiai, Managing Partner and Chief Investment Officer of Steamboat Capital, has 22 years of investing and corporate finance experience [4][5] - Jeff Rose, Chief Operating Officer and Chief Financial Officer of Steamboat Capital, has 23 years of financial experience and a background in corporate law [6]

Core Viewpoint - Medifast's recent earnings report indicates a significant decline in both revenue and earnings, raising concerns about the company's future performance and market position [2][3][4]. Financial Performance - Medifast reported a fourth-quarter loss of $1.65 per share, which was wider than the Zacks Consensus Estimate of a loss of 76 cents per share [3]. - Net revenues for the quarter were $75.1 million, reflecting a year-over-year decline of 36.9%, although it exceeded the Zacks Consensus Estimate of $70.8 million [4]. - The average revenue per active earning OPTAVIA Coach increased by 6.2% year over year to $4,664, despite the overall revenue decline [4]. Operational Challenges - The total number of active earning OPTAVIA coaches decreased by 40.6% year over year to 16,100, attributed to client acquisition challenges and increased competition from GLP-1 medications in the weight-loss market [5]. - Gross profit fell to $52.1 million, down 40.9% year over year, with a gross margin of 69.4%, compared to 74.1% in the prior year [6]. Cost Management - Selling, general, and administrative expenses decreased by 31.5% year over year to $59.9 million, primarily due to lower sales volumes and fewer active coaches [7]. - Despite the decline in absolute terms, SG&A expenses rose to 79.8% of revenue, reflecting reduced fixed-cost leverage and higher event and restructuring costs [8]. Financial Health - As of December 31, 2025, Medifast had cash, cash equivalents, and investment securities totaling $167.3 million, with no debt and total shareholders' equity of $198.9 million [9]. Future Outlook - For the first quarter of 2026, Medifast expects revenues between $65 million and $80 million, with a loss per share projected between 15 cents and 70 cents [11]. - For the full year 2026, revenues are anticipated to range from $270 million to $300 million, with a loss per share expected between $1.55 and $2.75 [11]. Market Sentiment - Following the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting by -358.33% [12]. - Medifast currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [14].

Core Insights - Medifast, Inc. (MED) reported fourth-quarter 2025 results with revenues exceeding estimates but a wider-than-expected loss per share, indicating challenges in the business [1][10]. Financial Performance - The company reported a quarterly loss of $1.65 per share, which was significantly worse than the Zacks Consensus Estimate of a loss of 76 cents per share. This loss included a tax provision charge of $12.1 million, equating to a loss of $1.10 per share [2]. - Net revenues were $75.1 million, reflecting a 36.9% decline year over year, primarily due to a decrease in the number of active earning OPTAVIA coaches. However, this figure surpassed the Zacks Consensus Estimate of $70.8 million [3][10]. - The average revenue per active earning OPTAVIA Coach increased by 6.2% year over year, rising to $4,664 from $4,391, indicating improved productivity among the remaining coaches [3]. Operational Challenges - The total number of active earning OPTAVIA coaches fell by 40.6% year over year to 16,100 from 27,100, attributed to difficulties in client acquisition and increased competition from GLP-1 medications in the weight-loss market [4]. - Gross profit decreased by 40.9% year over year to $52.1 million, with a gross margin of 69.4%, down from 74.1% in the previous year. This decline was due to a loss of fixed cost leverage and a one-time restructuring charge [5]. Cost Management - Selling, general, and administrative (SG&A) expenses decreased by 31.5% year over year to $59.9 million, driven by a reduction in coach compensation and marketing expenses. However, SG&A as a percentage of revenue increased to 79.8% due to fixed-cost leverage loss and higher event costs [6][7]. Financial Health - As of December 31, 2025, Medifast had cash, cash equivalents, and investment securities totaling $167.3 million, with no debt and total shareholders' equity of $198.9 million, indicating a stable financial position despite operational losses [8]. 2026 Outlook - For 2026, Medifast projects revenues between $270 million and $300 million, with an anticipated loss per share ranging from $1.55 to $2.75. The first-quarter 2026 revenue is expected to be between $65 million and $80 million, with a loss per share between 15 cents and 70 cents [10][11].

Core Insights - Medifast, Inc. (MED) is expected to report a significant decline in both revenue and earnings for the fourth quarter of fiscal 2025, with revenues estimated at $70.8 million, reflecting a 40.5% decrease year-over-year [1][9] - The consensus estimate for earnings per share has worsened to a loss of 76 cents, down from a profit of 10 cents in the same quarter last year [2][9] Factors Influencing Results - A key factor impacting performance is the decline in the active earning OPTAVIA coach base, attributed to challenges in client acquisition and increased competition from GLP-1 medications for weight loss [3][9] - Operating leverage is under pressure due to lower sales volumes, leading to a projected gross margin contraction of 790 basis points to 66.2% for the fourth quarter [4] - The company's strategic shift towards a broader metabolic health positioning may present near-term execution challenges, despite aiming to align with emerging health trends [5] Positive Indicators - Some operating metrics have shown signs of stabilization, such as moderating declines in revenue per active earning coach and positive early responses to initiatives like the Premier+ pricing and auto-ship program [6] - Medifast maintains a strong balance sheet, which provides financial flexibility for product innovation and digital enhancements, potentially cushioning fourth-quarter results [6]

Core Insights - Medifast® (NYSE: MED) is recognized for its OPTAVIA lifestyle system, which is based on scientific principles and personalized coaching [1] - The company celebrates the health transformation of Tiffany Howard, who was recently featured in People magazine, showcasing the effectiveness of its program [1] Company Overview - Medifast focuses on health and wellness, offering a comprehensive program that integrates science-backed nutrition and sustainable habit-building [1] - The OPTAVIA program aims to reverse metabolic dysfunction through personalized coaching and nutrition [1]

Core Insights - Medifast, Inc. (MED) experienced a significant year-over-year revenue decline of 36.2% in Q3 FY25, with revenue dropping to $89.4 million due to a sharp decrease in active earning OPTAVIA coaches [1][8] - The active coach base fell by 35% to 19,500, and the average revenue per active earning coach decreased by 1.9% to $4,585, indicating pressure on the company's coach-driven business model [1][8] Financial Performance - The company reported a revenue decline of 36.2% in Q3 FY25, primarily attributed to the reduction in active OPTAVIA coaches [1][8] - The Zacks Consensus Estimate for MED's current fiscal-year earnings indicates a year-over-year decline of 158.7% [10] Strategic Initiatives - To counteract the challenges, the company implemented rightsizing actions in October aimed at improving margins, with expectations for coach growth to re-emerge in six to nine months [2] - Medifast anticipates an inflection point in revenue growth by Q4 FY25, with management expecting growth in revenue per active earning coach within the next six months [2][4] Coaching and Digital Investments - The company emphasizes the value of personalized coaching through initiatives like the Premier+ pricing structure and the EDGE leadership program, which are designed to enhance coach productivity [3] - Ongoing investments in digital platforms, including app enhancements and reporting tools, are aimed at improving visibility into client progress and coach performance [3] Market Position - Medifast's shares have declined by 15% over the past six months, compared to a 10.4% decline in the industry [5] - The company trades at a forward price-to-sales ratio of 0.35, significantly lower than the industry's average of 1.05 [7]

Core Insights - Medifast, Inc. reported third-quarter 2025 results with revenues exceeding estimates but a wider-than-expected loss per share, indicating a year-over-year decline in both metrics [1][11] - The company is transitioning its focus from weight loss to metabolic health, aiming to address underlying metabolic issues and tap into a larger market [1][11] Financial Performance - The company reported a quarterly loss of $0.21 per share, which was significantly worse than the Zacks Consensus Estimate of a loss of $0.01, marking a reversal from a profit of $0.10 per share in the same quarter last year [2][11] - Net revenues were $89.4 million, down 36.2% year over year, primarily due to a decrease in active earning OPTAVIA coaches, although this figure surpassed the consensus estimate of $86 million [3][11] - The average revenue per active earning OPTAVIA Coach decreased to $4,585 from $4,672, attributed to challenges in client acquisition linked to the rise of GLP-1 medications for weight loss [3][4] Operational Metrics - The number of active earning OPTAVIA coaches fell by 35% to 19,500 from 30,000 in the prior year, reflecting ongoing difficulties in client acquisition [4][11] - Gross profit was $62.2 million, down 41.2% year over year, with a gross margin of 69.5%, a decline of 590 basis points due to fixed cost leverage loss and product reformulation reserves [5][11] - Selling, general and administrative expenses (SG&A) decreased by 36% year over year to $66.2 million, driven by lower OPTAVIA coach compensation and reduced marketing costs [6][11] Margin Analysis - SG&A as a percentage of revenues increased by 20 basis points year over year to 74.1%, primarily due to fixed cost leverage loss [7][11] - The loss from operations was $4.1 million, representing a loss margin of 4.6% compared to an operating income of $2.1 million and a margin of 1.5% in the prior-year period [8][11] Financial Health - As of September 30, 2025, the company had cash, cash equivalents, and investment securities totaling $173.5 million, with no debt and total shareholders' equity of $214.7 million [9][11] Future Outlook - For the fourth quarter of 2025, Medifast expects revenues between $65 million and $80 million, with a projected loss per share ranging from $0.70 to $1.25 [12][11]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $89.4 million, a decrease of 36.2% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA coaches [16][21] - Gross profit decreased 41.2% year-over-year to $62.2 million, with a gross profit margin of 69.5%, down 590 basis points compared to the prior year [16][17] - Net loss for Q3 2025 was $2.3 million, or $0.21 loss per diluted share, compared to net income of $1.1 million, or $0.10 per share in the year earlier period [21] Business Line Data and Key Metrics Changes - Active earning OPTAVIA coaches decreased by 35% year-over-year, ending the quarter with approximately 19,500 coaches [16] - Average revenue per active earning OPTAVIA coach was $4,585, a year-over-year decrease of 1.9% [16] Market Data and Key Metrics Changes - The weight loss and wellness industry is experiencing a shift due to the rise of GLP-1 medications, which has changed consumer conversations around obesity and health [4][6] - Over 90% of US adults are metabolically unhealthy, presenting a significant opportunity for the company to redefine wellness [6] Company Strategy and Development Direction - The company is evolving from a weight loss focus to a broader emphasis on metabolic health, aiming to help clients not only lose weight but also improve their metabolic health [9][10] - Plans to launch significant product innovations using metabolic synchronization science and next-generation ingredients are underway, with expectations to bring new products to market next year [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's direction, highlighting a strong balance sheet with no debt and over $170 million in cash and investments [14][15] - The company anticipates a return to growth in 2025, with expectations for improved revenue per active earning coach in Q4 2025 [33][35] Other Important Information - The company is investing in digital platforms to enhance the coaching and client experience, providing better visibility into client progress and coach performance [12][13] - The Edge Leadership Development Program aims to improve coach productivity and stability, focusing on creating and duplicating high-performing Executive Directors [12][29] Q&A Session Summary Question: How will the company ensure consistent messaging among coaches regarding the new focus on metabolic dysfunction? - The company has conducted studies to show how its program can reverse metabolic dysfunction and is training coaches to communicate this effectively [23][24] Question: Can you elaborate on the Edge program and its incentive structure? - The Edge program focuses on creating and duplicating Executive Directors to improve productivity and revenue [29] Question: How does the company view the impact of economic softness on consumer spending for health programs? - Management noted that consumers continue to prioritize health spending, despite economic challenges, and the program remains relevant for those using GLP-1 drugs [36][37]

Core Insights - Medifast, Inc. (MED) is strategically focusing on health, nutrition, and lifestyle coaching, expanding its portfolio of nutritionally-balanced meals and supplements tailored to diverse consumer needs [1][10] - The company is enhancing its OPTAVIA coaching network to improve customer acquisition, retention, and re-engagement, streamlining coach development and introducing intuitive incentives [2][10] - Medifast is adopting an integrated approach by launching new product lines (ACTIVE and ASCEND) and enhancing its digital platforms to modernize coach economics and product pricing [3][10] - The company aims to revitalize its coach and customer base through enhanced tools and data-driven support, positioning itself as a holistic partner in lifestyle transformation [4] Financial Performance - Medifast's shares have declined by 17.3% year to date, compared to a 7.2% dip in the industry [7] - The forward price-to-sales ratio for MED is 0.36X, significantly lower than the industry average of 1.03X [8] - The Zacks Consensus Estimate for MED's 2025 earnings per share (EPS) indicates a year-over-year decline of 126.6%, while the 2026 estimate shows growth of 17.4% [9][11] - Current estimates for EPS in 2025 and 2026 have decreased over the past 30 days [9]

Core Insights - Medifast's Q2 2025 results showed both net sales and earnings beating estimates, despite year-over-year declines in both metrics [2][3] - The company reported a significant drop in the number of active earning OPTAVIA coaches, impacting revenues [4][5] Financial Performance - Quarterly earnings were reported at 22 cents per share, with adjusted earnings at four cents per share, surpassing the Zacks Consensus Estimate of break-even earnings [3] - Net revenues totaled $105.6 million, a decline of 37.4% year-over-year, but exceeded the Zacks Consensus Estimate of $95 million [4] - Gross profit was $76.6 million, down 37.9% year-over-year, with a gross margin of 72.6%, a decrease of 60 basis points [6] - Selling, general and administrative expenses (SG&A) fell 40.8% year-over-year to $77.7 million, primarily due to reduced OPTAVIA coach compensation [7] - The loss from operations improved to $1.1 million, representing 1% of revenues compared to 4.7% in the previous year [8] Financial Health - As of June 30, 2025, Medifast had cash, cash equivalents, and investment securities totaling $162.7 million, with no debt and total shareholders' equity of $216 million [9] Future Outlook - The company anticipates third-quarter 2025 revenues between $70 million and $90 million, with expected losses ranging from 60 cents to break-even [10] - There has been a downward trend in estimates, with a consensus estimate shift of -116.67% [11][12] Industry Context - Medifast operates within the Zacks Food - Miscellaneous industry, where competitor Lamb Weston reported a revenue increase of 4% year-over-year [15] - Lamb Weston is also experiencing a downward trend in earnings estimates, with a Zacks Rank of 4 (Sell) [16]